Monday, November 21, 2011

Regeneration After a Stroke Requires Intact Communication Channels Between Brain Hemispheres

Source: Max-Planck-Gesellschaft
Date: November 21, 2011

Summary:

The structure of the corpus callosum, a thick band of nerve fibres that connects the two halves of the brain with each other and in this way enables the rapid exchange of information between the left and right hemispheres, plays an important role in the regaining of motor skills following a stroke. A study by scientists from the Max Planck Institute for Neurological Research and the Department of Neurology at the University Hospital of Cologne currently published in the journal Human Brain Mapping has shown that in stroke patients with particularly severely impaired hand movement, this communication channel between the two brain hemispheres in particular was badly damaged.

Tuesday, November 15, 2011

Researchers uncover mechanism that regulates human pluripotent stem cell metabolism

Source: University of California - Los Angeles Health Sciences
Date: November 15, 2011

Summary:

Human pluripotent stem cells, which can develop into any cell type in the body, rely heavily on glycolysis, or sugar fermentation, to drive their metabolic activities. In contrast, mature cells in children and adults depend more on cell mitochondria to convert sugar and oxygen into carbon dioxide and water during a high energy-producing process called oxidative phosphorylation for their metabolic needs.

How cells progress from one form of energy production to another during development is unknown, although a finding by University of California Los Angeles stem cell researchers provides new insight for this transition that may have implications for using these cells for therapies in the clinic.

Based mostly on visual appearance, it had been assumed that pluripotent stem cells contained undeveloped and inactive mitochondria, which are the energy-producing power plants that drive most cell functions. It was thought that stem cell mitochondria could not respire, or convert sugar and oxygen into carbon dioxide and water with the production of energy. This led most scientists to expect that mitochondria matured and gained the ability to respire during the transition from pluripotent stem cells into differentiated body cells over time.

Surprisingly, UCLA stem cell researchers discovered that pluripotent stem cell mitochondria respire at roughly the same level as differentiated body cells, although they produced very little energy, thereby uncoupling the consumption of sugar and oxygen from energy generation. Rather than finding that mitochondria matured with cell differentiation, as was anticipated, the researchers uncovered a mechanism by which the stem cells converted from glucose fermentation to oxygen-dependent respiration to achieve full differentiation potential.

The four-year study appears in the Nov. 15, 2011 issue of The EMBO Journal, a peer-reviewed journal of the European Molecular Biology Organization.

Monday, November 14, 2011

Stem Cell Study Helps Clarify the Best Time for Therapy to Aid Heart Attack Survivors

Source: Mayo Clinic
Date: November 14, 2011

Summary:


ORLANDO, Fla. — A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function. This is the first study to systematically examine the timing and method of stem cell delivery and provides vital information for the field of cell therapy. The results were presented this morning at the 2011 Scientific Sessions of the American Heart Association Meeting in Orlando, Fla. They also will be published online in JAMA to coincide with the presentation.

Results of trial using adult stem cells for heart failure triple researchers’ projections

Source: Brigham and Women's Hospital
Date: November 14, 2011

Summary:

ORLANDO, Fla. – Patients suffering from heart failure due to a previous myocardial infarction showed an average of 12 percent improvement one year following an investigative treatment that involved infusing them with their own stem cells. The results triple the 4 percent improvement average the researchers projected for the Phase I trial.

Results of the trial are published today (Nov. 14) in The Lancet and concurrently presented at the American Heart Association Scientific Sessions in Orlando, Fla. They are the first report of administering subjects’ own cardiac stem cells in humans; previous studies have used stem cells harvested from bone marrow.

Self-Organized Pituitary-Like Tissue from Mouse ES Cells

Source: RIKEN
Date: 14 November 2011

Summary:

The possibility that functional, three-dimensional tissues and organs may be derived from pluripotent cells, such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), represents one of the grand challenges of stem cell research, but is also one of the fundamental goals of the emerging field of regenerative medicine. New research has shown that when ES cells are cultured under the appropriate conditions, they can be driven to self-organize into complex, three-dimensional tissue-like structures that closely resemble their physiological counterparts, a remarkable advance for the field.

New work by Hidetaka Suga of the Division of Human Stem Cell Technology, Yoshiki Sasai, Group Director of the Laboratory for Organogenesis and Neurogenesis, and others has unlocked the most recent achievement in self-organized tissue differentiation, steering mouse ESCs to give rise to tissue closely resembling the hormone-secreting component of the pituitary, known as the adenohypophysis, in vitro. Conducted in collaboration with Yutaka Oiso at the Nagoya University Graduate School of Medicine, this work was published in Nature.

Phase I trial shows adult stem cell heart treatment three times more effective than expected

Source: University of Louisville
Posted: November 14, 2011 09:03 AM

Summary:

Patients who suffered from heart failure due to a heart attack showed an average of 12 percent improvement in heart function one year after they underwent an investigative treatment that involved infusing them with their own stem cells. Pre-trial projections were for a 4 percent improvement average. University of Louisville researcher Roberto Bolli, the lead investigator on the Phase I clinical trial, will present the findings today at the American Heart Association Scientific Sessions in Orlando, Fla. He also is lead author on a paper set for publication today in The Lancet.

Thursday, November 10, 2011

Einstein Researchers Discover Key To Cell Specialization

Source: Albert Einstein College of Medicine
Date: November 10, 2011

Summary:

(BRONX, NY) — Researchers at the Albert Einstein College of Medicine of Yeshiva University have uncovered a mechanism that governs how cells become specialized during development. Their findings could have implications for human health and disease and appear in the November 10 online edition of the journal Cell.

A fundamental question in biology is how a fertilized egg gives rise to many different cells in the body, such as nerve, blood and liver. By providing insight into that process, known as differentiation, the findings by the Einstein researchers are relevant to cancer, stem cell research and regenerative medicine.

The scientists studied cell differentiation in the fruit fly, Drosophila melanogaster. They found that cell specialization depends on a pair of proteins that act as super regulators of proteins that were already known—one super-regulating protein encouraging a cell to differentiate and the other trying to hold back the process.

Stem cell approach primes immune system to fight cancer

Source: Oxford University
Date: 10 November 2011

Summary:

Stem cell techniques have been used in the lab as a new way of priming the body’s own immune cells to attack cancer, in a proof-of-principle study by Oxford University scientists. The technical advance opens up the possibility of using stem cells derived from a patient’s skin as a source of key immune cells, called dendritic cells, which can orchestrate an immune response against a tumour. But much further work would be needed to turn this into a therapy ready to be used with cancer patients.

The Oxford researchers used recently established techniques to turn skin cells from a healthy adult back into a stem cell state. These ‘induced pluripotent stem (iPS) cells’ are capable of renewing themselves indefinitely and can be coaxed to form any cell type – muscle, nerve, heart tissue, etc.

Dr. Paul Fairchild and Dr Kate Silk prompted the human iPS cells to form dendritic cells using an approach that would be suitable for clinical use. That is, no animal-based material or supplements to aid growth were used. After providing the dendritic cells with components of a melanoma, the team showed the cells could initiate a full immune response to melanoma markers in cell cultures in the lab.

The study was funded by the UK Medical Research Council and the Oxford Martin School, and is published in the journal Gene Therapy.

Thursday, November 03, 2011

Gene Therapy Shows Promise as Hemophilia Treatment in Animal Studies

Source: Wake Forest Baptist Medical Center
Date: November 3, 2011

Summary:

WINSTON-SALEM, N.C. – – For the first time, researchers have combined gene therapy and stem cell transplantation to successfully reverse the severe, crippling bleeding disorder hemophilia A in large animals, opening the door to the development of new therapies for human patients. Researchers at Wake Forest Baptist Medical Center’s Institute for Regenerative Medicine, collaborating with other institutions, report in Experimental Hematology that a single injection of genetically-modified adult stem cells in two sheep converted the severe disorder to a milder form.

Monday, October 31, 2011

New Evidence for Spinal Membrane as a Source of Stem Cells May Advance Treatment of Spinal Cord Injuries

Source: Wiley-Blackwell
Date: October 31, 2011

Summary:

Durham, NC – Italian and Spanish scientists studying the use of stem cells for treating spinal cord injuries have provided the first evidence to show that meninges, the membrane which envelops the central nervous system, is a potential source of self-renewing stem cells. The research, published in STEM CELLS, develops the understanding of cell activation in central nervous system injuries; advancing research into new treatments for spinal injuries and degenerative brain disorders.

Researchers Find Regulatory T-Cell Clue To Help Prevent Graft-Versus-Host Disease

Source: H. Lee Moffitt Cancer Center & Research Institute
Date: October 31, 2011

Summary:


TAMPA, Fla. - Graft-versus-host disease (GVHD) is a serious risk in many kinds of cell transplants, including for stem cell transplants carried out when stem cells are partially depleted of conventional T cells, which play an important role in the immune system. Now, in a study published in a recent issue of the journal Blood, researchers at Moffitt Cancer Center have tested a process by which T regulatory cells (Tregs) can be "expanded" to help prevent GVHD.

Thursday, October 27, 2011

Lung Stem Cells Offer Therapeutic Clues

Source: Harvard Medical School
Date: October 27, 2011

Summary:

Guided by insights into how mice recover after H1N1 flu, researchers at Harvard Medical School and Brigham and Women's Hospital, together with researchers at A*STAR of Singapore, have cloned three distinct stem cells from the human airways and demonstrated that one of these cells can form into the lung's alveoli air sac tissue. What's more, the researchers showed that these same lung stem cells are rapidly deployed in a dynamic process of lung regeneration to combat damage from infection or chronic disease. The findings will be reported in the Oct. 28 issue of Cell.

Erasing Signs of Aging in Human Cells Now a Reality

Source: INSERM (Institut national de la santé et de la recherche médicale)
Date: October 27, 2011

Summary:

Scientists have recently succeeded in rejuvenating cells from elderly donors (aged over 100). These old cells were reprogrammed in vitro to induced pluripotent stem cells (iPSC) and to rejuvenated and human embryonic stem cells (hESC): cells of all types can again be differentiated after this genuine "rejuvenation" therapy. The results represent significant progress for research into iPSC cells and a further step forwards for regenerative medicine.

Inserm's AVENIR "Genomic plasticity and aging" team, directed by Jean-Marc Lemaitre, Inserm researcher at the Functional Genomics Institute (Inserm/CNRS/Université de Montpellier 1 and 2) performed the research. The results were published in Genes & Development on November 1, 2011.

Monday, October 24, 2011

Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial

Source: Neuralstem, Inc.
Date: October 24, 2011

Summary:

ROCKVILLE, Md. -- Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing safety data from the first 12 patients, the Food and Drug Administration (FDA) has granted approval for the trial to advance to transplanting patients in the cervical (upper back) region. Until now, patients have received injections in the lumbar (lower back) region only. Earlier this summer, the trial's Safety Monitoring Board unanimously approved moving to the cervical injection phase. The trial will now advance to the final two cohorts of patients with ALS, all of whom will be transplanted in the cervical region of the spine.

Thursday, October 20, 2011

Geron Presents Clinical Data Update from GRNOPC1 Spinal Cord Injury Trial

Source: Geron Corporation
Date: October 20, 2011

Summary:

MENLO PARK, Calif., - Geron Corporation today announced two presentations on the company's ongoing Phase 1 clinical trial of its human embryonic stem cell-based therapy, GRNOPC1, in patients with spinal cord injury. Safety data were presented at the Pre-Conference Symposia of the joint 2011 American Congress of Rehabilitation Medicine and American Society of Neuro-Radiology Annual Meeting in Atlanta, GA. A second presentation was given at the Working 2 Walk 2011 conference in Rockville, MD. The presentations were given by Joseph Gold, Ph.D., Geron's Senior Director of Neurobiology and Stem Cell Therapies and Linda Jones, P.T., M.S., Geron's Senior Clinical Trials Manager for GRNOPC1.

New Role of Vascular Endothelial Growth Factor in Regulating Skin Cancer Stem Cells

Source: Libre de Bruxelles, Universit
Date: October 20, 2011

Summary:

One of the key questions in cancer is the identification of the mechanisms that regulate cancer stem cells and tumor growth.

In a study published in Nature, researchers led by Cédric Blanpain, MD/PhD, FNRS/FRS researcher and WELBIO investigator at the IRIBHM, Université libre de Bruxelles, Belgium, in collaboration with the groups of Peter Carmeliet (VIB/K.U.Leuven) and Jody J. Haigh (VIB/UGent) have identified a new role for Vascular Endothelial Growth Factor (VEGF) in regulating skin cancer stem cells.

Skin squamous cell carcinomas are amongst the most frequent cancers in humans. Recent studies suggest that skin squamous cell carcinoma, like many other human cancers, contain particular cancer cells, known as cancer stem cells, that present increased self-renewal potential that sustain tumor growth. Little is known about the mechanisms that regulate cancer stem cell functions.

To dissect the mechanisms that regulate cancer stem cells, Beck and colleagues determined which genes are preferentially expressed by cancer stem cell of skin tumors. They found that VEGF, a molecule known to regulate the formation of new vessels, is expressed at high level by skin cancer stem cells, which are located in close contact to the blood vessels. Administration of an antibody that decreases new blood vessel formation to mice presenting skin tumors results in a reduction of the pool of cancer stem cells leading to a reduction of the tumor size, demonstrating that vascular cells regulate skin cancer stem cell functions.

To determine whether VEGF secretion by cancer stem cells directly regulates the function of cancer stem cells, the authors genetically removed VEGF specifically in tumour cells, and found that upon VEGF ablation, skin cancer stem cells were rapidly lost due to a defect in their renewal properties, leading to tumour regression. “It was extremely exciting to see the complete disappearance of these tumors only two weeks after the treatment” said Benjamin Beck, the first author of the Nature paper.

The authors also found that Neuropilin 1, a VEGF receptor, is also highly expressed by skin cancer stem cells, and showed that Neuropilin 1 expression by cancer stem cells is critical to promote cancer stem cell renewal and tumour growth. In addition, the authors found that Neuropilin 1 is also essential for tumour formation, demonstrating the critical role of Neuropilin 1 during both cancer initiation and tumor growth.

Altogether this new study provides novel and important insights into the mechanisms by which VEGF controls tumour growth.

Thursday, October 13, 2011

Understanding the Beginnings of Embryonic Stem Cells Helps Predict the Future

Source: Baylor College of Medicine
Date: October 13, 2011

Summary:

HOUSTON -- Ordinarily, embryonic stem cells exist only a day or two as they begin the formation of the embryo itself. Then they are gone. In the laboratory dish, however, they act more like perpetual stem cells – renewing themselves and exhibiting the ability to form cells of almost any type, a status called totipotency.

Scientists at Baylor College of Medicine showed that laboratory-grown cells express a protein called Blimp1, which represses differentiation to somatic or regular tissue cells during germ cell development. Studies of these cells show that they also express other genes associated with early germ cell specification. A report on their work published online today in the journal Current Biology. It will appear in the Oct. 25 print edition of the journal.

New Method Isolates Best Brain Stem Cells to Treat MS

Source: University at Buffalo
Date: October 13, 2011

Summary:

-- A precise method has been developed that prospectively isolates just the stem cells that can treat multiple sclerosis and childhood diseases caused by the brain's inability to make myelin.

--After analzying genes in different stem cell types, the scientists searched for and found the genes that were most likely to differentiate into stem cells that make myelin.

--The human stem cells were then successfully injected into the brains of mice with MS.

--The new method brings the prospect of clinical trials that much closer, the scientists say.

BUFFALO, N.Y. – The prospect of doing human clinical trials with stem cells to treat diseases like multiple sclerosis may be growing closer, say scientists at the University at Buffalo and the University at Rochester, who have developed a more precise way to isolate stem cells that will make myelin.

Myelin is the crucial fatty material that coats neurons and allows them to signal effectively. The inability to make myelin properly is the cause of MS as well as rare, fatal, childhood diseases, such as Krabbe's disease. The research, published online and in the October issue of Nature Biotechnology, overcomes an important barrier to the use of stem cells from the brain in treating demyelinating diseases.

Precision with Stem Cells a Step Forward for Treating M.S., Other Diseases

Source: University of Rochester Medical Center
Date: October 13, 2011

Summary:

Scientists have improved upon their own previous world-best efforts to pluck out just the right stem cells to address the brain problem at the core of multiple sclerosis and a large number of rare, fatal children’s diseases. Details of how scientists isolated and directed stem cells from the human brain to become oligodendrocytes – the type of brain cell that makes myelin, a crucial fatty material that coats neurons and allows them to signal effectively – were published online and in the October issue of Nature Biotechnology by scientists at the University of Rochester Medical Center and the University at Buffalo.

Stem Cells from Cord Blood Could Help Repair Damaged Heart Muscle

Source: University of Bristol
Date: 13 October 2011

Summary:

New research has found that stem cells derived from human cord blood could be an effective alternative in repairing heart attacks. At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient's own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and aging. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart attack.

The study, led by Professor Raimondo Ascione, Chair of Cardiac Surgery & Translational Research in the School of Clinical Sciences at the University of Bristol, is published online in Stem Cell Reviews & Reports. The study, funded by the British Heart Foundation (BHF) and the National Institute for Health Research (NIHR), found that it is possible to expand up to seven-fold, in vitro, rare stem cells (called CD133+) from human cord blood and then grow them into cardiac muscle cells.

The findings could have major implications on future treatment following a heart attack given that cells obtained from adults following a heart attack may be less functional due to aging and risk factors.